Number of people screened and patients treated according to NGO and period of intervention.

<p>Number of people screened and patients treated according to NGO and period of intervention.</p

New cases of HAT reported in Sudan.

<p>Period 1910–2010.</p

Classification of human African trypanosomiasis-endemic countries according to cases reported in 2009.

<p>Classification of human African trypanosomiasis-endemic countries according to cases reported in 2009.</p

Number of participants enrolled (by country).

<p><i>T.b.g.</i>, <i>T.b. gambiense</i>; <i>T.b.r.</i>, <i>T.b. rhodesiense</i>.</p

Localities of collection sites of specimens for the HAT specimen biobank (yellow dots).

<p>Dark grey indicates HAT-endemic countries. The bold black line shows the theoretical separation of <i>T.b. gambiense</i> and <i>T.b. rhodesiense</i> areas.</p

Percentage of second stage <i>T. b. gambiense</i> patients treated according to drug used.

<p>Eflornithine versus melarsoprol (2003–2009).</p

Summary of specimens stored in ICAReB, Institut Pasteur, Paris.

<p>P1, case stage 1; P2, case stage2; Px, case stage not determined; C, controls; S1, suspects' initial visit; Sx, suspects' follow-up visits.</p

Institutional rate use of eflornithine.

<p>National Sleeping Sickness Control Programmes versus nongovernmental organizations (2003–2009).</p

Evolution of reported cases of both forms of human African trypanosomiasis (1998–2009).

<p>Evolution of reported cases of both forms of human African trypanosomiasis (1998–2009).</p

The distribution of the risk of <i>T</i>. <i>b</i>. <i>gambiense</i> infection.

<p>Periods 2003–2007 and 2008–2012.</p